The share price in Arrowhead Pharmaceuticals Inc. jumped by more than 48% in the two months since it hit its lowest value of the past year. On Oct. 10, ...
Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Kostas ...
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...
Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...
On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...
Investor's Business Daily on MSN12d
Sarepta Therapeutics Sees RS Rating Rise To 75A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...
On Wednesday, Needham, a well-regarded investment firm, adjusted its stock price target for Sarepta Therapeutics (NASDAQ:SRPT), a biopharmaceutical company specializing in rare genetic diseases. The ...
Arrowhead secured a $500 million deal with Sarepta, including a $325 million stock purchase and potential milestone payments, boosting its financial stability. Arrowhead's NDA for plozasiran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback